Literature DB >> 18400340

Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.

Laura Bungener1, Felix Geeraedts, Wouter Ter Veer, Jeroen Medema, Jan Wilschut, Anke Huckriede.   

Abstract

Clinical trials with pandemic influenza vaccine candidates have focused on aluminium hydroxide as an adjuvant to boost humoral immune responses. In this study we investigated the effect of aluminium hydroxide on the magnitude and type of immune response induced by whole-inactivated virus (WIV) vaccine. Balb/c mice were immunized once with a range of antigen doses (0.04-5 microg) of WIV produced from A/PR/8 virus, either alone or in combination with aluminium hydroxide. The hemagglutination inhibition (HI) titers of mice receiving WIV+aluminium hydroxide were 4-16-fold higher than HI titers in mice receiving the same dose of WIV alone, indicating the boosting effect of aluminium hydroxide. WIV induced a TH1 skewed humoral and cellular immune response, characterized by strong influenza-specific IgG2a responses and a high number of IFNgamma-secreting T cells. In contrast, immunization with WIV adsorbed to aluminium hydroxide resulted in skewing of this response to a TH2 phenotype (high IgG1 levels and a low number of IFNgamma-producing T cells). To assess the effect of the observed immune response skewing on viral clearance from the lungs mice immunized once with 1 microg WIV without or with aluminium hydroxide were challenged with A/PR/8 virus 4 weeks later. The immunized mice showed a significant decrease in viral lung titers compared to control mice receiving buffer. However, despite higher antibody titers, mice immunized with WIV adsorbed to aluminium hydroxide suffered from more severe weight loss and had significantly higher virus loads in their lung tissue than mice receiving WIV alone. Major difference between these groups of mice was the type of immune response induced, TH2 instead of TH1, indicating that a TH1 response plays a major role in viral clearance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400340     DOI: 10.1016/j.vaccine.2008.02.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  57 in total

1.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

2.  A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model.

Authors:  Beth C Holbrook; Jong R Kim; Lance K Blevins; Matthew J Jorgensen; Nancy D Kock; Ralph B D'Agostino; S Tyler Aycock; Mallinath B Hadimani; S Bruce King; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2016-06-08       Impact factor: 5.422

3.  Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes.

Authors:  Hsin-Yu Liao; Shih-Chi Wang; Yi-An Ko; Kuo-I Lin; Che Ma; Ting-Jen Rachel Cheng; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

4.  Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.

Authors:  Naihan Chen; Matthew D Gallovic; Pamela Tiet; Jenny P-Y Ting; Kristy M Ainslie; Eric M Bachelder
Journal:  J Control Release       Date:  2018-09-24       Impact factor: 9.776

5.  A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.

Authors:  Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Michael A Collier; Rebekah Watkins-Schulz; Ning Cheng; Clément N David; Charles E McGee; Gregory D Sempowski; Ivo Shterev; Karen McKinnon; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  J Control Release       Date:  2017-11-21       Impact factor: 9.776

6.  Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.

Authors:  Mariana Baz; Mukesh Samant; Hakima Zekki; Pascale Tribout-Jover; Martin Plante; Anne-Marie Lanteigne; Marie-Eve Hamelin; Corey Mallett; Barbara Papadopoulou; Guy Boivin
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

7.  Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration.

Authors:  Merry Christie; Raul M Torres; Ross M Kedl; Theodore W Randolph; John F Carpenter
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

8.  Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.

Authors:  Felix Geeraedts; Vinay Saluja; Wouter ter Veer; Jean-Pierre Amorij; Henderik W Frijlink; Jan Wilschut; Wouter L J Hinrichs; Anke Huckriede
Journal:  AAPS J       Date:  2010-03-02       Impact factor: 4.009

9.  Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus.

Authors:  Victor C Huber; Loren H Kleimeyer; Jonathan A McCullers
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

10.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.